Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TargetRx Inc.

This article was originally published in Start Up

Executive Summary

The founders of TargetRx think pharmaceutical firms ought to start early and continue doing marketing research throughout a product's life cycle. The start-up plans to seek the opinions of a wide range of specialists--negative as well as positive opinions, from prescribers and non-prescribers alike--which management says will yield vital strategic insights..

You may also be interested in...



E-Medical Market Research

Internet-based market research has become the norm in many areas of commerce, but the pharmaceutical industry is only just beginning to adopt the practice. The trend is being pushed forward by young companies that claim they can help drugmakers get from doctors the sorts of information they value--only more efficiently and cost-effectively than ever before. The web will also enable the collection of new types of information and insights, these start-ups claim.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Spero Therapeutics: Remodeling Antibiotics

Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel